← Back to patent-cliff list
Lutetium-177 zadavotide guraxetan
Tier C — Watch / tradeLutetium-177 zadavotide guraxetan
Curium Us Llc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：PSMA
Indications (approved)：Prostate cancer, Castration-resistant prostate cancer
Regional status
US
Phase III
2022-02-14
EU
Phase III
2022-02-14
China
Phase I
2026-03-18
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lutetium-177 zadavotide guraxetan?
Approved indications include: Prostate cancer, Castration-resistant prostate cancer.
When does the Lutetium-177 zadavotide guraxetan patent expire?
No public expiry year is available for Lutetium-177 zadavotide guraxetan yet; this page updates once verified.
How do I get a quote for Lutetium-177 zadavotide guraxetan intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05